EUVIMEDEUVIMED entdecken
Crossref

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)

Jorge Hernando, Carlos Lopez, Alejandro Garcia-Alvarez, Santiago Aguín Losada, Olga Martínez-Sáez, Carlos Gonzalez-Perez, Ricardo López-Almaraz, Raúl Sánchez Morillas, Joseba Rebollo Liceaga, Laura Ferreira Freire, Miriam Pavon-Mengual, María Ruiz Vico und 4 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Jorge Hernando und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hepatobiliary Pancreatic Cancer and Endocrine Tumors, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Ho…. Hauptthemen laut MEDLINE: Neoplasms, Pyrazoles, Pyrimidines, Protein Kinase Inhibitors. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPyrazolesPyrimidinesProtein Kinase InhibitorsHumansFemaleMaleChild, PreschoolAdolescentChildAgedAdultMiddle AgedInfantSpainReceptor, trkAAged, 80 and overRetrospective StudiesYoung AdultReceptor, trkBReceptor, trkCOncogene Proteins, FusionMembrane GlycoproteinsTreatment Outcome

Stichwörter der Autor:innen

LarotrectinibNTRKReal-worldSolid tumorsTRK

Substanzen

larotrectinibPyrazolesReceptor, trkAPyrimidinesProtein Kinase InhibitorsNTRK1 protein, humanReceptor, trkBReceptor, trkCNTRK3 protein, humanOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Medical Oncology, Hepatobiliary Pancreatic Cancer and Endocrine Tumors, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Neuroendocrine and Endocrine Tumor Tr…
  • Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Spain.
  • Medical Oncology, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
  • Department of Medical Oncology, IDIBAPS, Hospital Clínic, Barcelona, Spain.
  • Department of Pediatric Hematology and Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • Pediatric Oncology/Haematology Unit, Hospital Universitario Cruces & Biobizkaia Health Research Institute, Barakaldo, Spain.

Förderung

  • Bayer

Zitieren

APA

Hernando, J., Lopez, C., Garcia-Alvarez, A., Aguín Losada, S., Martínez-Sáez, O., Gonzalez-Perez, C., López-Almaraz, R., Sánchez Morillas, R., Rebollo Liceaga, J., Ferreira Freire, L., Pavon-Mengual, M., Ruiz Vico, M., López-Gómez, M., Morilla, I., Rodríguez-Abreu, D., & Capdevila, J. (2026). Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116252

Vancouver

Hernando J, Lopez C, Garcia-Alvarez A, Aguín Losada S, Martínez-Sáez O, Gonzalez-Perez C, et al. Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK). European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116252

BibTeX
@article{Hernando2026,
  author = {Hernando, Jorge and Lopez, Carlos and Garcia-Alvarez, Alejandro and Aguín Losada, Santiago and Martínez-Sáez, Olga and Gonzalez-Perez, Carlos and López-Almaraz, Ricardo and Sánchez Morillas, Raúl and Rebollo Liceaga, Joseba and Ferreira Freire, Laura and Pavon-Mengual, Miriam and Ruiz Vico, María and López-Gómez, Miriam and Morilla, Idoia and Rodríguez-Abreu, Delvys and Capdevila, Jaume},
  title = {Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK)},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116252}
}
Kostenlos starten →